Core Viewpoint - VolitionRx Limited has received a notice of non-compliance from NYSE American regarding its continued listing standards due to insufficient stockholders' equity, requiring a plan to regain compliance by August 6, 2027 [1][2] Compliance Requirements - The company is not in compliance with Section 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide, which mandates stockholders' equity of at least $2.0 million, $4.0 million, and $6.0 million respectively, based on reported losses over recent fiscal years [1] - Volition must submit a compliance plan by March 8, 2026, detailing actions to regain compliance [1] Delisting Proceedings - If the plan is not submitted or accepted, or if compliance is not achieved by the deadline, NYSE American will initiate delisting proceedings [1] - The common stock will continue to trade under the symbol "VNRX" with an added designation of ".BC" indicating "below compliance" status [1] Business Operations - The notice does not impact the ongoing business operations or reporting requirements of the company with the U.S. Securities and Exchange Commission [1] - Volition is committed to regaining compliance and plans to submit a detailed plan to the NYSE American [1]